UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-----------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 19, 2006
ICOS CORPORATION
(Exact name of registrant as specified in its charter)
Washington 0-19171 91-1463450
- --------------------------------------------------------------------------------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) File Number) Identification No.)
22021 - 20th Avenue S.E., Bothell, WA 98021
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip code)
(425) 485-1900
- --------------------------------------------------------------------------------
(Registrant's telephone number, including area code)
Not Applicable
- --------------------------------------------------------------------------------
(Former name, former address and former fiscal year, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
ITEM 2.02. Results of Operations and Financial Condition
On October 19, 2006, Lilly ICOS LLC, our 50/50 joint venture with
Eli Lilly and Company, which is marketing Cialis(R) (tadalafil) for the
treatment of erectile dysfunction, issued a press release announcing its
financial results for the quarter ended September 30, 2006. A copy of the press
release is furnished as Exhibit 99 to this report and is incorporated herein by
reference.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
ICOS CORPORATION
Date: October 19, 2006 By: /S/ MICHAEL A. STEIN
---------------- --------------------
Michael A. Stein
Senior Vice President and
Chief Financial Officer
EXHIBIT INDEX
Exhibit No. Description
99 Press Release of Lilly ICOS LLC dated October 19,
2006, reporting Lilly ICOS' financial results for the
quarter ended September 30, 2006.